There is a whole generation of women who learned one very simple lesson about hormone therapy.
Hormones are dangerous.
Breast cancer. Blood clots. Stroke. Dementia. Don’t mess with them unless you absolutely have to.
For a lot of women, that message came through their mothers. For others, it came directly from their doctors. And for many Gen X women now walking into appointments asking what the hell happened to their sleep, memory, metabolism, libido, mood, and ability to regulate their body temperature, that message is still sitting in the room with them.
Except there is a problem. The story we were handed was never nearly as simple as “hormones are dangerous.” And more than twenty years later, menopause care is still trying to catch up.
The study behind the fear
Most of this story traces back to the Women’s Health Initiative, or WHI, published in the early 2000s.
If you have heard hormone therapy discussed as dangerous, there is a good chance some version of the WHI is lurking underneath that conversation, whether anyone names the study or not.
What often gets left out is what the researchers were actually studying. The WHI was not primarily designed to answer the question most women sitting in a menopause appointment want answered:
“Is hormone therapy an appropriate option for someone like me who is dealing with symptoms now?”
The women enrolled were, on average, in their early 60s. Many had already been postmenopausal for 10, 15, or even 20 years before starting hormone therapy. And that matters… a lot.
A 48-year-old woman whose periods are becoming irregular, who suddenly cannot sleep and who wants to discuss treatment for perimenopause is not the same clinical situation as a woman beginning hormone therapy for the first time at 63.
Yet somehow, over the years, a lot of those differences disappeared from the conversation. So did another important detail.
The WHI did not test every form of hormone therapy available today. In fact the only combined therapy used oral conjugated equine estrogen with medroxyprogesterone acetate, a synthetic progestin. It did not study the commonly used combination of transdermal estradiol and micronized progesterone that many women receive today.
Different women.
Different timing.
Different formulations.
Different routes of administration.
Those differences matter because they change how the study applies to women considering hormone therapy today. And this is where the original message got oversimplified, because those facts don’t make a good headline, but “Hormones cause cancer” does. And that is where things went sideways.
